The charts of these 35 patients were reviewed and comprise the basis of this report. During the same ten-year period a diagnosis of pulmonary tuberculosis was made in 469 patients. This represents an incidence of Myco kansasii infection of 7.2 percent of all mycobacterial disease.
J)uri ng the ten-year period from 1962 through July 1972, 35 patients at the University of Kansas Medical Center had a diagnosis of active pulmonary disease due to Mycobacterium kansasii. To be included, each patient met the following criteria: (1) Parenchymal infiltrates were demonstrated on chest roentgenograms. (2) Myco kansasii was cultured from sputum on two or more occasions or from biopsy specimens. ( 3) The course of the disease and response to therapy were consistent with Myco kansasii infection.
The charts of these 35 patients were reviewed and comprise the basis of this report. During the same ten-year period a diagnosis of pulmonary tuberculosis was made in 469 patients. This represents an incidence of Myco kansasii infection of 7.2 percent of all mycobacterial disease.
OBsREvATI0N5
The ages of the patients ranged from 8 to 76, with a mean of 48 years. Twenty-five (71 percent) were male and ten patients (29 percent) were female. This preponderance of males to females with Myco kansasii infections has been noted by others,1-3 but as yet unexplained. Thirty (86 percent) were white and five patients (14 percent) were black. Twentyfour of 35 patients (69 percent) were symptomatic at the time of admission. Cough was present in 12 of 35 (34 percent), with a variety of chest complaints occurring less frequently. Eleven of 35 patients (31 percent) were asymptomatic and were admitted because of abnormal findings on chest x-ray films. by plain posterior-anterior (PA) roentgenography or by laminography. Nine patients had single cavities, and 11 had multiple cavities, for a total of 20 of 30 patients with cavitation (61 percent). Cavitation is commonly found in Myco kansasii infections and has been reported to occur in over 80 percent of patients.5 6 Twenty-two patients (67 percent) had bilateral disease and 11 patients (33 percent) had unilateral disease. The initial chest radiographs were reviewed and the extent of the disease was recorded according to the number of zones revealing abnormal shadows. Each lung field was divided into an upper, middle and lower zone on the posteroanterior view. Only one zone was involved in 17 patients, two zones in 9 and three zones or more in 7.
In 33 of 35 patients (94 percent) Myco kansasii was recovered from two or more sputum samples. Other culture sources included gastric washing in one patient, bone marrow in one patient, skin biopsy in one patient and from lymph nodes in three patients. Three of the patients in the series had cultural and clinical evidence of disseminated Myco kansasii infection. In two of these patients, the organism was cultured from the sputum in addition to recovery from disseminated sites. Table 2 lists the various drugs used to treat 33 of the 35 patients. Two patients were transferred to a tuberculosis sanatorium for treatment shortly after the diagnosis was established and are thus excluded. All 33 patients received INH, with 8 receiving 300 mg, 21, 600 mg and four, 900 mg. The three-drug regimen consisting of INH 600 mg, PAS 12 gm and streptomycin 0.5 to 1.0 gm daily was used in 60-70 percent of this group of patients. The total streptomyciri dosage in each patient varied and ranged from 22 to 415 gm, with a mean dose of 99 gm. On follow-up, if the patient's chest roentgenogram failed to show improvement or if the sputum cultures remained positive, subsequent secondary drugs were added to the regimen. Ethambutal, cycloserine and ethionamide were most commonly used, with ethambutal used in 17 of 33 patients (51.5 percent). Pyrazinamide and rifampin were each used in three patients. One of the early treated patients in this series was given a two-month course of erythromycm because of a suggestion that it might be effective in treating photochromogenic infections. However, this drug was subsequently shown to be ineffective. Table 3 shows the number of drugs that each patient was given in an effort to eradicate the organism. These data are compared with the mean number of positive sputum cultures and the mean sputum conversion time in weeks for each drug During clinical follow-up in 31 of 35 patients (89 percent) on chemotherapy, there has not been one instance of bacteriologic, roentgenographic or clinical relapse. These patients have been on chemotherapy for a mean time of 24.3 months, with a range of 1.5 to 68 months. Therapy was discontinued in five of this group and the patients have now been observed for a mean of 13.5 months. The total clinical follow-up period for these 31 patients ranged from 1.5 to 82 months, with a mean of 27.2 months. This total absence of clinical relapse can be explained in part by the use of multiple drug regimens administered over a prolonged period in a clinical setting where periodic visits for close clinical surveillance was possible. Persistence of cavitation after sputum conversion is a feature of this disease in which surgery is performed-but not without complications. Harrison'#{176} advises caution after experience with 30 procedures in 24 patients. In most series the major complications involved bronchopleural fistulae and empyema formation. Bates4 reports that 4 of 25 patients (16 percent) had complications following operation. Table 4 lists the results of medical and surgical therapy in this series. Four of 33 patients (12 percent) had operation for a persistent open cavity. As seen in Table 5 , the surgical procedures included two lobectomies, one lobectomy plus resection of the superior segment and one extrapleural pneumonectomy. The one complication was a bronchopleural fistula which occurred in the patient who had the superior segment removed in addition to a lobectomy. These four patients were culture-negative at the time of operation and have remained so until the present. Three of them have been observed for a mean of 62 months, chemotherapy having been discontinued for a mean of 16.2 months. One patient who had a pneumonectomy has continued on drugs for a total of 55 months. None of the four patients have had a relapse. In no case was the Myco kansasii infection or its treatment felt by the clinician in charge of the patient to be the direct cause of death. Three of the patients had an underlying hematologic malignancy for which they were also receiving chemotherapy.
